- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07804563
Recreational Football for Young-to-middle-aged Inactive Men
Euro Football Fitness - Recreational Football as a Broad-spectrum Health Intervention for 30-50-year-old Inactive Men
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Randomization:
The participants were randomized 1:2 to the control or the intervention groups, respectively. Randomization was performed by a researcher not involved in data collection or outcome assessment. Blinding of participants and instructors, coaches and the investigation team leading the training sessions was not feasible in this type of exercise intervention. Outcome evaluators, who were not involved in intervention delivery or group allocation, were blinded to group assignment throughout the assessment time points (baseline and 12 weeks).
Statistical analysis:
Both intention-to-treat (ITT) and per-protocol (PP) approaches were applied. The ITT analysis included all randomized participants; missing post-intervention values were handled using multiple imputation. The PP analysis included only participants who attended ≥66% of the prescribed sessions. Descriptive statistics were calculated using observed data and are reported as mean ± SD. The distribution of continuous variables was inspected visually using histograms and Q-Q plots, and normality was further assessed using the Shapiro-Wilk test. Model assumptions were evaluated by visual inspection of residual plots and Q-Q plots of model residuals.
Outcome variables were analysed using linear mixed-effects models to account for repeated measurements within participants. For each outcome, Time (pre vs post), Group (intervention vs control), and the Time × Group interaction were specified as fixed effects, with a participant-specific random intercept to model within-subject clustering, according to the general form: outcome ~ Time + Group + Time × Group + (1 | participant). Fixed effects were evaluated using omnibus F-tests with Satterthwaite-approximated degrees of freedom, and model estimates are reported as regression coefficients (b) with standard errors and 95% confidence intervals. Where appropriate, post hoc pairwise comparisons of estimated marginal means were used to decompose significant effects, with multiplicity controlled using Bonferroni adjustment. Model fit was summarised using marginal and conditional R², and variance components were reported as random-intercept and residual variance. The intraclass correlation coefficient (ICC) was calculated to quantify the proportion of variance attributable to between-participant differences.
Effect sizes were expressed as partial eta squared (ηp²) for omnibus effects and Cohen's d for within- and between-group contrasts, using the standard deviation (SD), not the standard error, as the standardiser to avoid inflation (Lakens, 2013). Cohen's d was interpreted as trivial (<0.20), small (0.20-0.49), moderate (0.50-0.79), and large (≥0.80), following Cohen's conventional thresholds (Cohen, 1988). Partial eta squared was interpreted as small (ηp² ≈ 0.01), moderate (ηp² ≈ 0.06), and large (ηp² ≈ 0.14) (Richardson, 2011). These thresholds were used only as descriptive guidelines, and effects were interpreted alongside the magnitude and precision of the estimated mean differences. All tests were two-sided, with statistical significance set at α = 0.05. Statistical analyses were performed using jamovi (version 2.6.23; The jamovi project, Sydney, Australia) and R packages (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) appropriate for each analysis.
To overcome the common limitation of low statistical power highlighted in previous recreational football interventions, a substantially larger sample size was deliberately recruited. This strategic design choice was undertaken not only to enhance the robustness of subgroup and ITT analyses but also to increase the precision of effect size estimates, thereby improving the generalizability of the findings.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- 30-50-year-old-males
- inactive (i.e., not exercising for more than 20 min on three or more days per week)
- with medical clearance from a physician to undertake moderate-to-vigorous intensity exercise
Exclusion Criteria:
- Cardiovascular or cerebrovascular disease
- Advanced retinopathy
- Renal failure
- Previous cardiovascular event
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental: Intervention group
Participants allocated to the intervention group undertook a 12-week recreational football-based exercise programme performed 2-3 times per week, with each session lasting 60 minutes, under the supervision of sports education graduates and the research team.
|
Participants allocated to the intervention group undertook a 12-week recreational football-based exercise programme performed 2-3 times per week, with each session lasting 60 minutes, under the supervision of sports education graduates and the research team.
Outros nomes:
|
|
Sem intervenção: No Intervention: Control group
Participants allocated to the control group were informed to maintain their current lifestyle and physical activity habits for the duration of the study.
No supervised exercise programme was provided by the research team during the 12-week intervention period.
Following the 12-week assessments, the control group participants were offered the opportunity to participate in the recreational football programme.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-groups differences at 12 weeks in maximal oxygen uptake
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Maximal oxygen uptake (mL/min/kg) was measured by pulmonary gas exchange measurements.
The participants performed an incremental treadmill test until voluntary exhaustion in a laboratory, according to a standardized incremental protocol.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-groups differences at 12 weeks in systolic blood pressure
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Systolic blood pressure (mmHg) was measured in a laboratory by an automatic upper arm blood pressure monitor (multiparameter patient monitor, Omron Z207, Kyoto, Japan) according to standardized procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in diastolic blood pressure
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Diastolic blood pressure (mmHg) was measured using an automatic upper arm blood pressure monitor (multiparameter patient monitor, Omron Z207, Kyoto, Japan) according to standardized procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in resting heart rate
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Resting heart rate (bpm) was measured using an automatic upper arm blood pressure monitor (multiparameter patient monitor, Omron Z207, Kyoto, Japan) according to standardized procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body mass was measured by a whole-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left arm total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left arm total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right arm total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right arm total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left leg total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left leg total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right leg total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right leg total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in gynoid total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Gynoid total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in android total mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Android total mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body fat mass was measured by a whole-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left arm fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left arm fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right arm fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right arm fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left leg fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left leg fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right leg fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right leg fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in gynoid fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Gynoid fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in android fat mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Android fat mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in in whole-body lean mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body lean mass was measured by a whole-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left arm lean mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left arm lean mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right arm lean mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right arm lean mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left leg lean mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left leg lean mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right leg lean mass
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right leg lean mass was measured by a regional-body dual-energy X-ray absorptiometry following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body bone mineral density was measured by dual-energy X-ray absorptiometry scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body bone mineral content was measured by dual-energy X-ray absorptiometry scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in lumbar spine bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Lumbar spine bone mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in lumbar spine bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Lumbar spine bone mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in femur bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Femur bone mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in femur bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Femur bone mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left arm bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left arm mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left arm bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left arm bone mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right arm bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right arm bone mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right arm bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right arm mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left leg bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left leg bone mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in left leg bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Left leg bone mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right leg bone mineral density
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right leg bone mineral density was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in right leg bone mineral content
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Right leg mineral content was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body total T-score
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body total T-score was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in whole-body total Z-score
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Whole-body total Z-score was measured by dual-energy X-ray absorptiometry regional scans following standard procedures.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in procollagen type-1 amino-terminal propeptide
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Plasma concentrations of biochemical bone turnover markers were analysed by chemiluminescence method using a fully automated immunoassay system.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in osteocalcin
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Plasma concentrations of biochemical bone turnover markers were analysed by chemiluminescence method using a fully automated immunoassay system.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in carboxy-terminal type-1 collagen crosslinks
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Plasma concentrations of biochemical bone turnover markers were analysed by chemiluminescence method using a fully automated immunoassay system.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in postural balance
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Postural balance was evaluated by the number of falls in a single-legged flamingo balance test.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in aerobic performance
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Aerobic performance (Yo-Yo intermittent endurance level 2 test total distance covered (m)) was evaluated on a football artificial grass pitch, according to a standardized protocol.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in lower body muscle strength
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Lower body muscle strength (standing long jump distance (cm)) was evaluated on a football artificial grass pitch, according to a standardized protocol.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in neck circumference
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Neck circumference was evaluated according to a standardized protocol.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in waist circumference
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Waist circumference was evaluated according to a standardized protocol.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in total cholesterol
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Total cholesterol (mg/dl) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in high-density lipoprotein cholesterol
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
High-density lipoprotein cholesterol (mg/dl) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in low-density lipoprotein cholesterol
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Low-density lipoprotein cholesterol (mg/dl) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in triglycerides
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Triglycerides (mg/dl) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in glycosylated haemoglobin
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Glycosylated haemoglobin (%) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in fasting blood glucose
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Fasting blood glucose (mg/dl) was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences at 12 weeks in fasting plasma insulin
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Fasting blood insulin (µmol/L) was determined was determined by an automated analyser.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Between-groups differences in physical activity levels
Prazo: [Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
Physical activity levels were measured utilizing the international physical activity questionnaire - short form.
|
[Time Frame: Baseline and 12 weeks after the beginning of the intervention]
|
|
Mean and peak relative heart rate
Prazo: [Time Frame: 12 weeks]
|
Mean and peak relative heart rate were measured for selected participants in the intervention group during selected training sessions of the exercise programme.
|
[Time Frame: 12 weeks]
|
|
Mean and peak absolute heart rate
Prazo: [Time Frame: 12 weeks]
|
Mean and peak absolute heart rate were measured for selected participants in the intervention group during selected training sessions of the exercise programme.
|
[Time Frame: 12 weeks]
|
|
Time (absolute and relative) spent in heart rate zones
Prazo: [Time Frame: 12 weeks]
|
Time (absolute and relative) spent in heart rate zones were measured for selected participants in the intervention group during selected training sessions of the exercise programme.
|
[Time Frame: 12 weeks]
|
|
Edwards TRIMP
Prazo: [Time Frame: 12 weeks]
|
Edwards TRIMP (AU) was determined for selected participants in the intervention group during selected training sessions of the exercise programme.
|
[Time Frame: 12 weeks]
|
|
Matches total distance covered
Prazo: [Time Frame: 12 weeks]
|
Matches total distance covered was measured for selected participants in the intervention group during selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Match accelerations
Prazo: [Time Frame: 12 weeks]
|
Accelerations performed were measured for selected participants in the intervention group during selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Match decelerations
Prazo: [Time Frame: 12 weeks]
|
Match decelerations performed were measured for selected participants in the intervention group selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Matches rating of perceived exertion
Prazo: [Time Frame: 12 weeks]
|
Rating of perceived exertion was measured for selected participants in the intervention group during selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Fun scores
Prazo: [Time Frame: 12 weeks]
|
Fun scores were measured for selected participants in the intervention group during selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Blood lactate
Prazo: [Time Frame: 12 weeks]
|
Blood lactate values were measured for selected participants in the intervention group during selected training sessions matches of the exercise programme
|
[Time Frame: 12 weeks]
|
|
Delayed Onset Muscle Soreness
Prazo: [Time Frame: 12 weeks]
|
Delayed Onset Muscle Soreness was measured for selected participants in the intervention group during the exercise programme
|
[Time Frame: 12 weeks]
|
|
Harms
Prazo: [Time Frame: 12 weeks]
|
Harms occurring during the exercise programme were registered.
|
[Time Frame: 12 weeks]
|
|
Attendance
Prazo: [Time Frame: 12 weeks]
|
Number and percentage of scheduled exercise sessions attended by each participant during the exercise programme.
|
[Time Frame: 12 weeks]
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Susana Póvoas, PhD, University of Maia
- Investigador principal: Peter Krustrup, PhD, University of Southern Denmark
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- EURO Football Fitness
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .